Literature DB >> 12537223

Metastatic thoracic lymph node carcinoma with unknown primary site.

Marc Riquet1, Cécile Badoual, Barthes Françoise le Pimpec, Antoine Dujon, Claire Danel.   

Abstract

BACKGROUND: Metastatic cancer in thoracic lymph nodes without a primary site is rare. The purpose of this study is to draw attention to this probably underestimated entity, to speculate on its possible origins, and to suggest guidelines for its treatment.
METHODS: Eight heavy smokers with no past medical history of cancer were diagnosed at operation to have malignant cells in intrathoracic lymph nodes (N1 or N2) with no primary site in the lung. All patients underwent an exploratory thoracotomy with a presumed diagnosis of lung cancer except one who presented with a middle lobe mucosa-associated lymphoid tissue lymphoma. We reviewed the type of surgical resection, histologic and immunohistochemical analysis of resected specimens, treatments, survival, and long-term results.
RESULTS: Resections performed were pneumonectomy (n = 4), lobectomy (n = 3), and bilobectomy (n = 1). All patients underwent complete mediastinal lymph node dissection. Lung resection was performed for mucosa-associated lymphoid tissue lymphoma (n = 1) and for tumorlike lesions that appeared to be tuberculoma (n = 1) and intrapulmonary metastatic lymph nodes (n = 6). Malignant cells were located in intrapulmonary lymph nodes alone (n = 3) or also in mediastinal lymph nodes in three other cases. All these tumors were cytokeratin-positive, demonstrating their epithelial nature. Pulmonary origin was confirmed in two cases (thyroid transcription factor 1-positive and thyroglobulin-negative). No other origin could be demonstrated by immunochemistry. Three patients died within the first year. All other patients are still alive without recurrence (Kaplan-Meier 5-year survival rate, 62.5%).
CONCLUSIONS: Frequency of metastatic cancer in thoracic lymph nodes without a primary site is probably underestimated because the cancer is routinely diagnosed by mediastinoscopy and considered as metastatic disease not amenable to operation. The origin of the disease, either pulmonary, endogenous, or from extrathoracic sites, is often difficult to assess. Nevertheless, our data confirm those of the literature and demonstrate that survival can be increased by operation. This implies diagnosis of the entity and consideration that thoracic lymph node involvement can apparently be isolated and therefore resectable.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12537223     DOI: 10.1016/s0003-4975(02)04119-x

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  7 in total

1.  Indolent metastatic squamous cell carcinoma of unknown primary in the intrathoracic lymph node: a case report and review of the literatures.

Authors:  Min Jin Kim; Sang Hyok Lim; Su Jung Han; Kang Hyug Choi; Sun Hyo Lee; Min Woo Park; HyeRan Kang; Ju Ock Na
Journal:  Tuberc Respir Dis (Seoul)       Date:  2015-01-29

2.  Outcomes of Stage III NSCLC with occult primary vs. known primary lesions.

Authors:  Paul B Romesser; Yonatan Bardash; Darren Buonocore; Jamie E Chaft; James Huang; David R Jones; Andreas Rimner; Abraham J Wu
Journal:  Lung Cancer       Date:  2018-11-17       Impact factor: 5.705

Review 3.  Lung Cancer Detected 5 Years after Resection of Cancer of Unknown Primary in a Mediastinal Lymph Node: A Case Report and Review of Relevant Cases from the Literature.

Authors:  Hidenori Kawasaki; Kazunari Arakaki; Naohiro Taira; Tomonori Furugen; Takaharu Ichi; Tomofumi Yohena; Tsutomu Kawabata
Journal:  Ann Thorac Cardiovasc Surg       Date:  2015-09-02       Impact factor: 1.520

4.  Mediastinal Neuroendocrine Carcinoma Slowly Growing for 8 Years after Surgical Resection of Esophageal Squamous Cell Carcinoma.

Authors:  Suguru Hirose; Naoyuki Hasegawa; Hitomi Kawai; Masamichi Yamaura; Tsuneo Mizui; Yoshiki Komatsu; Masaomi Nagase; Masashi Sato; Junji Hattori; Masato Endo; Yoshiyuki Yamamoto; Kazunori Ishige; Kuniaki Fukuda; Ichinosuke Hyodo; Yuji Mizokami
Journal:  Intern Med       Date:  2020-07-07       Impact factor: 1.271

5.  Cisplatin plus Docetaxel Chemotherapy for Thoracic Lymph Node Metastasis from Cancer of Unknown Primary - Experience of Three Cases.

Authors:  Takashi Kobayashi; Tomonobu Koizumi; Akihiro Kitaguchi; Orie Hatayama; Kenji Tsushima; Kazuhisa Urushihata; Hiroshi Yamamoto; Masayuki Hanaoka; Keishi Kubo; Takayuki Honda; Kazuhiro Oguchi
Journal:  Case Rep Oncol       Date:  2009-05-15

6.  Relapsed cervicomediastinal lymph node carcinoma with an unknown primary site treated with TS-1 alone: a case report.

Authors:  Toshiki Yajima; Ryoichi Onozato; Yoshinori Shitara; Akira Mogi; Shigebumi Tanaka; Hiroyuki Kuwano
Journal:  BMC Res Notes       Date:  2013-12-27

7.  Lymph node cancer of the mediastinum with a putative necrotic primary lesion in the lung: a case report.

Authors:  Daichi Shikata; Takahiro Nakagomi; Rumi Higuchi; Yujiro Yokoyama; Toshio Oyama; Taichiro Goto
Journal:  World J Surg Oncol       Date:  2018-04-02       Impact factor: 2.754

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.